scholarly journals A randomized, double blind, placebo controlled, split patch study to evaluate the effects of platelet rich plasma on alopecia areata

2018 ◽  
Vol 6 (8) ◽  
pp. 2696
Author(s):  
Bushra Khan ◽  
Ramesh Sharma ◽  
Milind A. Borkar
Keyword(s):  
Alopecia Areata ◽  
Small Volume ◽  
Platelet Rich Plasma ◽  
Patch Area ◽  
Self Assessment ◽  
Double Blind ◽  
Double Spin ◽  
Gradual Loss ◽  
Normal Hair ◽  
Patient Self Assessment

Background: Alopecia Areata is a T-cell–mediated autoimmune, often reversible disease in which the gradual loss of protection provided by immune privilege of the normal hair follicle plays an important role. It manifests as smooth, slightly erythematous (peach color) or normal-colored alopecic patches with short broken hair at the margins. It involves scalp most commonly, although other regions of body may be affected. Platelet rich plasma is an autologous concentration of platelets with a greater count in a small volume of plasma. Study aimed to evaluate the safety and efficacy of PRP therapy in Alopecia Areata.Methods: In this randomised, placebo controlled, split patch study, 30 patients of AA were recruited and injected with 1-1.5ml of autologous PRP made by double spin method into half the bald patch area and other half with placebo using insulin syringe once a month for 3 months. Outcome was assessed at the end of study by clinical photographs as regrowth of hair, dermoscopy findings as reduction in black dots, yellow dots and exclamation hair and Physician and patient self-assessment score.Results: Administration of autologous PRP has led to observable improvement in 20% case of PRP and only 3.3% of control cases. Decrease in number of dystrophic hair and hair regrowth with PRP was seen in 20% cases and in 17% patches.Conclusions: PRP in our setting was found to be minimally effective, but more efficacious than no treatment, and safe for AA patients.

Intramuscular Treatment of Migraine Attacks Using Diclofenac Sodium: A Crossover Clinical Trial

1987 ◽  
Vol 15 (1) ◽  
pp. 44-48 ◽  
Author(s):  
E. Del Bene ◽  
M. Poggioni ◽  
U. Garagiola ◽  
V. Maresca
Keyword(s):  
Clinical Trial ◽  
Diclofenac Sodium ◽  
Crossover Design ◽  
Placebo Administration ◽  
Self Assessment ◽  
Double Blind ◽  
Condition Evaluation ◽  
Double Blind Clinical Trial ◽  
Carry Over ◽  
Patient Self Assessment

This was a double-blind clinical trial, with a crossover design, to compare the efficacy of a non-steroidal anti-inflammatory drug, diclofenac sodium, intramuscularly administered, and placebo in the treatment of migraine attacks. The drug was administered to 40 patients once a day in three consecutive migraine attacks. If pain still remained after 6 h following administration the patient was given a 100 mg diclofenac sodium suppository, in open condition. Evaluation was by a complete medical examination performed by the physician and by the patient completing a specially designed self-assessment card. A total of eight patients dropped out of the trial (all during placebo administration): three due to poor compliance, four for refusal to continue and one because no further migraine attacks developed. Results were analysed after having checked the absence of both period and carry-over effects. In all cases diclofenac sodium was more effective than placebo ( P < 0.01). This was also confirmed by data obtained from the patient self-assessment cards ( P < 0.001) and by preferences expressed by patients at the end of the trial ( P < 0.001). Tolerance to the drug was similar to that of placebo.

The Effectiveness of Topical Antibacterials in Acne: A Double-Blind Clinical Study

1978 ◽  
Vol 6 (1) ◽  
pp. 72-77 ◽  
Author(s):  
E Franz ◽  
S Weidner-Strahl
Keyword(s):  
Clinical Study ◽  
Blind Study ◽  
Double Blind Study ◽  
Self Assessment ◽  
Double Blind ◽  
Patient Self Assessment

In a double-blind study, three groups of patients with mild to moderate acne were treated for eight weeks with topical acne creams containing the antibacterials triclosan or triclosan plus propylene phenoxetol. The formula without antibacterials served as the control. Total-face lesion counts, evaluation of the overall degree of inflammation of the lesions, and patient self-assessment showed the added efficacy of the antibacterials when incorporated into the control.

A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata

2013 ◽  
Vol 169 (3) ◽  
pp. 690-694 ◽  
Author(s):  
A. Trink ◽  
E. Sorbellini ◽  
P. Bezzola ◽  
L. Rodella ◽  
R. Rezzani ◽  
...  
Keyword(s):  
Alopecia Areata ◽  
Platelet Rich Plasma ◽  
Double Blind ◽  
Double Blind Placebo

The Effect of Warfarin Sodium on the Duration of Platelet Aggregation

1967 ◽  
Vol 18 (03/04) ◽  
pp. 766-778 ◽  
Author(s):  
H. J Knieriem ◽  
A. B Chandler
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Platelet Rich Plasma ◽  
Healthy Adults ◽  
Double Blind Study ◽  
Double Blind ◽  
Warfarin Sodium

SummaryThe effect of the administration of warfarin sodium (Coumadin®) on the duration of platelet aggregation in vitro was studied. Coumadin was given for 4 consecutive days to 10 healthy adults who were followed over a period of 9 days. The duration of adenosine diphosphate-induced platelet aggregation in platelet-rich plasma, the prothrombin time, and the platelet count of platelet-rich plasma were measured. Four other healthy adults received placebos and participated in a double-blind study with those receiving Coumadin.Although administration of Coumadin caused a prolongation of the prothrombin time to 2 or 21/2 times the normal value, a decrease in the duration of platelet aggregation was not observed. In most individuals who received Coumadin an increase in the duration of platelet aggregation occurred. The effect of Coumadin on platelet aggregation was not consistently related to the prothrombin time or to the platelet count. In the placebo group there was a distinct relation between the duration of platelet aggregation and the platelet count in platelet-rich plasma.The mean increase in the duration of platelet aggregation when compared to the control value before medication with Coumadin was 37.7%. In the placebo group there was a mean increase of 8.4%. The difference between the two groups is significant (p <0.001). Increased duration of platelet aggregation also occurred in two individuals who received Coumadin over a period of 10 and 16 days respectively.

Sign in / Sign up

Export Citation Format

Share Document